Globenewswire·2025-10-30 20:00Core Points - GENFIT has announced its intention to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq Stock Market, effective prior to the opening of trading on November 20, 2025 [1] - The company remains committed to its listing on Euronext Paris, which has been its primary trading market since April 2014 [2][3] Company Strategy - The decision to delist from Nasdaq is aimed at streamlining operations and focusing resources, enhancing operational efficiency in line with the current pipeline development stage [3][8] - GENFIT plans to file a Form 25 to initiate the removal of the ADS listing, which will be effective ten days after the filing [3] Financial and Operational Details - GENFIT's financial foundation is supported by the successful development and commercialization of elafibranor for Primary Biliary Cholangitis (PBC) [3] - The company intends to maintain high standards of corporate governance and transparency while complying with French and European financial market regulations [3] Information for ADS Holders - ADS holders will have until approximately February 6, 2026, to surrender their ADSs for the underlying ordinary shares, with applicable fees for cancellation and cable services [4][5] - After the delisting, the Depositary may sell the underlying ordinary shares, and ADS holders must surrender their securities to obtain payment of the sale proceeds [6][8] Company Overview - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with a history of over two decades in liver disease research and development [10][11] - The company has developed therapeutic assets targeting conditions such as Acute on-chronic Liver Failure (ACLF) and has a diagnostic franchise for detecting metabolic dysfunction-associated steatohepatitis [11][12]